INBX Inhibrx, Inc.

Our mission is to discover and develop effective biologic treatments for people with life-threatening conditions and to evolve Inhibrx into a commercial-stage biotechnology company with a differentiated and sustainable product portfolio.

$25.69  -0.38 (-1.46%)
As of 06/25/2021 09:30:59 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  08/19/2020
Outstanding shares:  37,810,751
Average volume:  287,874
Market cap:   $1,011,437,589
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    45720L107
ISIN:        US45720L1070
Sedol:      BK1MBC3
Valuation   (See tab for details)
PE ratio:   -12.64
PB ratio:   16.27
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy